Moneycontrol
Last Updated : Mar 13, 2018 10:55 AM IST | Source: Moneycontrol.com

Zydus receives final approval from USFDA for Tizanidine tablets USP

Zydus Cadila has received a final approval from the USFDA to market Tizanidine tablets USP in the strength of 2 mg and 4 mg.

 
 
live
  • bselive
  • nselive
Volume
Todays L/H
More

Zydus Cadila has received a final approval from the USFDA to market Tizanidine tablets USP in the strength of 2 mg and 4 mg.

At 10:54 hrs Cadila Healthcare was quoting at Rs 394.75, up Rs 5.35, or 1.37 percent.

The share touched its 52-week high Rs 558.00 and 52-week low Rs 373.05 on 12 June, 2017 and 06 February, 2018, respectively.

Currently, it is trading 29.26 percent below its 52-week high and 5.82 percent above its 52-week low.

Market capitalisation stands at Rs 40,412.24 crore. Source : BSE
First Published on Mar 13, 2018 10:55 am
Sections
Follow us on
Available On